A型肉毒毒素治疗先天性寨卡综合征相关脑瘫痉挛的疗效观察：一项观察性研究。
Botulinum Toxin Type A in the Spasticity of Cerebral Palsy Related to Congenital Zika Syndrome: An Observational Study.
机构信息
Universidade Federal da Bahia, Salvador, Brazil.
Escola Bahiana de Medicina e Saúde Pública, Salvador, Brazil.
出版信息
Dev Neurorehabil. 2022 Apr;25(3):162-169. doi: 10.1080/17518423.2021.1960917. Epub 2021 Aug 13.
PURPOSE
Investigate the effect of botulinum toxin type-A (BoNT-A) on spasticity and motor performance in children with Cerebral Palsy (CP) related to Congenital Zika Syndrome (CZS).
METHODS
Prospective longitudinal observational study of 34 children with CP referred for BoNT-A treatment. Outcomes were evaluated with a muscle tone assessment scale (Modified Ashworth Scale - MAS) and the Patients' Global Impression of Improvement (PGI-I) scale.
RESULTS
Mean age was 32.06 ± 3.07 months and 85% were classified as Gross Motor Function Classification System (GMFCS) V. Primitive reflexes were present in 56% of the sample. The majority of the parents (97.9%) reported improvement in range of motion or reduction in spasticity after treatment with botulinum toxin. No side effects were recorded. When compared to the baseline, median reduction in the MAS was 0.5 (IQR = 0).
CONCLUSIONS
The findings of this study suggest that BoNT-A may effectively promote functional improvements and reduce muscle tone, improving the child's and family's quality of life.
目的
研究 A 型肉毒毒素（BoNT-A）对先天性寨卡综合征（CZS）相关脑瘫（CP）患儿痉挛和运动功能的影响。
方法
对 34 名接受 BoNT-A 治疗的 CP 患儿进行前瞻性纵向观察研究。采用改良 Ashworth 量表（MAS）和患者整体印象改善量表（PGI-I）评估疗效。
结果
平均年龄为 32.06±3.07 个月，85%为粗大运动功能分级系统（GMFCS）V 级。56%的患儿存在原始反射。大多数家长（97.9%）表示治疗后运动范围改善或痉挛减轻。未记录到任何副作用。与基线相比，MAS 的中位数降低 0.5（IQR=0）。
结论
本研究结果表明，BoNT-A 可能有效促进功能改善，降低肌肉张力，提高患儿及其家庭的生活质量。
Zotero 插件